Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.
For people living with Atrial Fibrillation (AF), the most common cardiac arrhythmia, current treatments have limited effectiveness and can cause serious side effects.
Ventricular Tachyarrhythmia (VT) and Ventricular Fibrillation (VF) sufferers must endure debilitating high-electrical energy shocks that can result in diminished heart function over time.
The Cardialen unpinning termination (UPT) therapy is designed to deliver a sequence of low-energy pulses timed to stop abnormal heart rhythms that may provide a more gentle therapy than current options.
CAUTION: Investigational Device. Limited by Federal (United States) law to investigational use only.